Live
FierceBiotechIcon ends internal accounting investigation, finds it overstated revenue in prior yearsFierceBiotechFDA extends Beren’s rare disease review after info request, further stretching sagaEndpoints NewsICON audit finds overstated revenue; Secretome and Psilera raise cashEndpoints News#ASCO26: After leaving Legend, Frank Fan is ready to showcase his next projectFierceBiotechHoth Therapeutics’ pivot to AI in space sees stock rocket after rebrandCellFarnesylation-driven KRAS phase separation promotes colon tumor growthCellStructural basis of Wnt signalosome extracellular complex assemblyEndpoints NewsNiowave’s $75M radioisotope facility; CordenPharma to buy AmbioPharmEndpoints NewsCharles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapyFierceBiotechHuman Longevity launches newco, teams with Insilico for AI-powered longevity researchFierceBiotechNovartis ‘always looking’ for further ways to shuttle drugs to brain despite run of recent dealsPromega BlogScreening Disease-Relevant Biology: How the Endo-GeneScreen Platform Uses Endogenous Protein Detection to Drive Drug Discovery
Agilent Feb 26, 2026

The Analyst Verdict: Agilent Technologies In The Eyes Of 9 Experts - Benzinga

The Analyst Verdict: Agilent Technologies In The Eyes Of 9 Experts - Benzinga

Original
Body unavailable. Use the original source.